Literature DB >> 20424942

Midkine regulation of the renin-angiotensin system.

Kenji Kadomatsu1.   

Abstract

Hypertension and chronic kidney disease are often associated. The pathogenesis of these diseases involves the renin-angiotensin system. We have recently reported that the growth factor midkine is a novel regulator of the renin-angiotensin system. Midkine is a heparin-binding growth factor so far implicated in neuronal differentiation, neuroprotection, cardioprotection, inflammation, and cancer development. In a mouse model of chronic kidney disease induced by 5/6 nephrectomy, midkine is produced in the lung and in turn upregulates angiotensin-converting enzyme expression. Hypertension associated with 5/6 nephrectomy is not observed in midkine-deficient mice. Conversely, supplemental administration of midkine to the deficient mice induces hypertension. This review describes the molecular characteristics of midkine and its significance in the renin-angiotensin system and the kidney-lung interaction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20424942     DOI: 10.1007/s11906-010-0092-8

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  17 in total

1.  Cross-talk between the kidney and the cardiovascular system.

Authors:  Kerstin Amann; Christoph Wanner; Eberhard Ritz
Journal:  J Am Soc Nephrol       Date:  2006-07-06       Impact factor: 10.121

2.  Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts.

Authors:  Hiroshi Banno; Yoshifumi Takei; Takashi Muramatsu; Kimihiro Komori; Kenji Kadomatsu
Journal:  J Vasc Surg       Date:  2006-09       Impact factor: 4.268

Review 3.  Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).

Authors:  Reto Krapf; Henry N Hulter
Journal:  Clin J Am Soc Nephrol       Date:  2009-02       Impact factor: 8.237

4.  The growth factor midkine regulates the renin-angiotensin system in mice.

Authors:  Akinori Hobo; Yukio Yuzawa; Tomoki Kosugi; Noritoshi Kato; Naoto Asai; Waichi Sato; Shoichi Maruyama; Yasuhiko Ito; Hiroyuki Kobori; Shinya Ikematsu; Akira Nishiyama; Seiichi Matsuo; Kenji Kadomatsu
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

Review 5.  TGF-beta and BMPR-II pharmacology--implications for pulmonary vascular diseases.

Authors:  Paul D Upton; Nicholas W Morrell
Journal:  Curr Opin Pharmacol       Date:  2009-03-25       Impact factor: 5.547

Review 6.  A new mouse model resembling human diabetic nephropathy: uncoupling of VEGF with eNOS as a novel pathogenic mechanism.

Authors:  T Nakagawa
Journal:  Clin Nephrol       Date:  2009-02       Impact factor: 0.975

Review 7.  Midkine and pleiotrophin in neural development and cancer.

Authors:  Kenji Kadomatsu; Takashi Muramatsu
Journal:  Cancer Lett       Date:  2004-02-20       Impact factor: 8.679

8.  Upregulation of the brain renin-angiotensin system in rats with chronic renal failure.

Authors:  M Nishimura; H Takahashi; M Yoshimura
Journal:  Acta Physiol (Oxf)       Date:  2007-04       Impact factor: 6.311

9.  Plasma midkine level is a prognostic factor for human neuroblastoma.

Authors:  Shinya Ikematsu; Akira Nakagawara; Yohko Nakamura; Miki Ohira; Masaki Shinjo; Satoshi Kishida; Kenji Kadomatsu
Journal:  Cancer Sci       Date:  2008-10       Impact factor: 6.716

Review 10.  Therapeutic strategies to slow chronic kidney disease progression.

Authors:  Elke Wühl; Franz Schaefer
Journal:  Pediatr Nephrol       Date:  2008-03-12       Impact factor: 3.714

View more
  5 in total

1.  The cytokine midkine and its receptor RPTPζ regulate B cell survival in a pathway induced by CD74.

Authors:  Sivan Cohen; Or-yam Shoshana; Einat Zelman-Toister; Nitsan Maharshak; Inbal Binsky-Ehrenreich; Maya Gordin; Inbal Hazan-Halevy; Yair Herishanu; Lev Shvidel; Michal Haran; Lin Leng; Richard Bucala; Sheila Harroch; Idit Shachar
Journal:  J Immunol       Date:  2011-12-02       Impact factor: 5.422

Review 2.  Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.

Authors:  G Herradón; C Pérez-García
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

3.  Elevated serum midkine levels in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients.

Authors:  Sema Ketenci; M Uygar Kalaycı; Bağnu Dündar; Recep Duranay; A Şükrü Aynacıoğlu
Journal:  Int Immunopharmacol       Date:  2022-06-09       Impact factor: 5.714

Review 4.  Physiology of Midkine and Its Potential Pathophysiological Role in COVID-19.

Authors:  Giulia Sanino; Martino Bosco; Giuseppe Terrazzano
Journal:  Front Physiol       Date:  2020-12-22       Impact factor: 4.566

Review 5.  Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review.

Authors:  Laura Bergantini; Alessandro Mainardi; Miriana d'Alessandro; Paolo Cameli; David Bennett; Elena Bargagli; Piersante Sestini
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.